December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
A Naked Dna Vaccine Using A New High Level Expression Vector Is More Efficacious Against Ocular Hsv-1 Infection Than The Corresponding Subunit (protein) Vaccine
Author Affiliations & Notes
  • H Ghiasi
    Ophthalmology Research Cedars-Sinai Medical Center Los Angeles CA
  • Y Osorio
    Los Angeles CA
  • AB Nesburn
    Los Angeles CA
  • J Cohen
    Los Angeles CA
  • SL Wechsler
    Los Angeles CA
  • Footnotes
    Commercial Relationships   H. Ghiasi, None; Y. Osorio , None; A.B. Nesburn , None; J. Cohen , None; S.L. Wechsler , None. Grant Identification: EY09224, the Discovery Fund for Eye Research, and
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3852. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H Ghiasi, Y Osorio, AB Nesburn, J Cohen, SL Wechsler; A Naked Dna Vaccine Using A New High Level Expression Vector Is More Efficacious Against Ocular Hsv-1 Infection Than The Corresponding Subunit (protein) Vaccine . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3852.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Compare the efficacy of immunization with "naked" DNA corresponding to the genes for HSV-1 glycoproteins gB, gC, gD, gE, and gI (5gP DNA) using the novel high expression plasmid pVR1055 (Vical, Inc, San Diego) with that of a corresponding 5gP protein (subunit) vaccine. Also, compare the effectiveness of the adjuvants Montanide ISA 51 (Seppic, France) and Montanide ISA 720 that have recently been approved for use in humans, with Freund's adjuvant, as regards immunization with our 5gP protein vaccine. Methods: BALB/c mice were vaccinated with 5gP DNA, or 5gP protein using either ISA 51, ISA 720, or Freund's as adjuvant. Neutralizing antibody titers were determined by plaque reduction assays. IL-2, IL-4, IL-12, and IFN-gamma levels were determined by ELISA following in vitro stimulation of spleen cells. Following ocular challenge with lethal dose of HSV-1 strain McKrae, virus replication in the eye, survival, blepharitis, and corneal scarring were determined. Results: Neutralizing antibody titers (approximately 1:800 to 1:1200), corneal scarring (trace), and survival (100%) were similar for all vaccine groups, including 5gP DNA. Compared to the other vaccine groups, the 5gP DNA group had less ocular virus replication as judged both by maximum virus titer and time of viral clearance. ISA 51 and Freund's produced similar protection against ocular virus replication. Interestingly ISA 720 appeared more efficacious than Freund's against ocular virus replication and eye disease. The 5gP DNA vaccinated mice had less blepharitis then any other group and had the highest levels of IL-12 and IFN-gamma. All vaccine groups had similar levels of IL-2. Conclusion: (1)When used as adjuvant for the 5gP protein vaccine, ISA 720, which is safe and already approved for human use, appeared to be more efficacious than Freund's adjuvant. (2)The 5gP DNA vaccine using the new pVR1055 plasmid vector appeared to be more efficacious than the corresponding protein subunit vaccine, regardless of adjuvant.

Keywords: 425 herpes simplex virus • 449 keratitis • 380 cytokines/chemokines 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.